Top

Published in:

16-08-2023 | Insulins

Targeting Retinol-Binding Protein 4 (RBP4) in the Management of Cardiometabolic Diseases

Authors: Cecilia Oluwamodupe, Adesola Oluwaseun Adeleye

Published in: Cardiovascular Toxicology | Issue 9-10/2023

Abstract

The ancient use of herbs for the treatment of various human diseases have been documented, with several scientific literatures supporting the use of medicinal plants. There is however a major concern about the phyto-constituents in the plants that performs the healing function and the mechanism by which it works for different ailments are still a research prospect. Cardiometabolic disease (CMD) is no doubt becoming more frequent globally and this is due to poor approach in therapy, contrary effects linked with intensive control, inept strategies with old drugs, inadequate control of some risk factors and lack of knowledge of the pathophysiological mechanisms that lead to this malaise. Retinol-binding protein 4 (RBP4) are predominantly secreted in the liver and adipose tissues and several researches have observed that elevation in serum levels of RBP4 often observed in obese experimental animals and human subjects causes CMD (obesity, insulin resistance, hyperlipidemia, etc.). RBP4 has gained special attention in the last 20 years in the field of metabolism research. This review aims to show research interaction of some medicinal plants targeting RBP4 in treating CMD and to encourage researchers, who are interested in CMD drug design, to focus on medicinal plants that inhibit the secretion of serum RBP4 in the adipose tissue for therapeutic approach to CMD. It also aims to identify the major bioactive compounds of plants that serves as a better and cheaper drug candidate for CMD and also study the signaling pathway which the plant material uses to regulate the metabolic consequences.

Adeleye, A. O. (2020). In vitro studies on antioxidant potential of aqueous extract of Bridelia ferruginea stem bark in brain and liver of wistar-albino rats using sodium nitroprusside as pro-oxidant. Asian Journal of Biochemistry, Genetics and Molecular Biology, 3(3), 39–45.CrossRef

Al Zarzour, R. H., et al. (2018). Adipocytokine regulation and antiangiogenic activity underlie the molecular mechanisms of therapeutic effects of Phyllanthus niruri against non-alcoholic fatty liver disease. Nutrients, 10(8), 1057.CrossRefPubMedCentral

Aly, O., Elias, T. R., Ashour, M. N., Agaibyi, M. H., Rasheed, W. I., Yassen, N. N., & Diab, Y. (2021). Antidiabetic and hepatoprotective activities of Bombax ceiba extract in obese rats with metabolic syndrome. Plant Archives, 21(1), 748–756.CrossRef

Bagalkotkar, G., et al. (2010). Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: A review. Journal of Pharmacy and Pharmacology, 58(12), 1559–1570.CrossRef

Balagopal, P., Graham, T. E., Kahn, B. B., Altomare, A., Funanage, V., & George, D. (2007). Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: Association with subclinical inflammation. Journal of Clinical Endocrinology, 92, 1971–1974. https://doi.org/10.1210/jc.2006-2712CrossRef

Berni, R., & Formelli, F. (1992). In vitro interaction of fenretinide with plasma retinol- binding protein and its functional consequences. FEBS Letters, 308, 43–45. https://doi.org/10.1016/0014-5793(92)81046-oCrossRefPubMed

Birdee, G. S., & Yeh, G. (2010). Complementary and alternative medicine therapies for diabetes: A clinical review. Clin. Diabetes, 28, 147–155.CrossRef

Blaner, W. S. (2007). STRA6, a cell-surface receptor for retinol-binding protein: The plot thickens. Cell Metabol., 5, 164–166. https://doi.org/10.1016/j.cmet.2007.02.006CrossRef

Bonanni, B., Lazzeroni, M., & Veronesi, U. (2007). Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Review of Anticancer Therapy, 7, 423–432. https://doi.org/10.1586/14737140.7.4.423CrossRefPubMed

10.

Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010). Discovery and development of therapeutic aptamers. Annual Review of Pharmacology and Toxicology, 50, 237–257. https://doi.org/10.1146/annurev.pharmtox.010909.105547CrossRefPubMed

11.

Brahmachari, G. (2011). Bio-flavonoids with promising antidiabetic potentials: A critical survey. Res. Signpost, 661, 187–212.

12.

Chen, J., Mangelinckx, S., Adams, A., Wang, Z., Li, W., & De Kimpe, N. (2015). Natural flavonoids as potential herbal medication for the treatment of diabetes mellitus and its complications. Natural Products Communications, 10, 187–200.

13.

Chen, L., Lu, X., El-Seedi, H., & Teng, H. (2019). Recent advances in the development of sesquiterpenoids in the treatment of type 2 diabetes. Trends in Food Science & Technology, 88, 46–56.CrossRef

14.

Cho, Y. M., Youn, B. S., Lee, H., Lee, N., Min, S. S., Kwak, S. H., Lee, H. K., & Park, K. S. (2006). Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care, 29, 2457–2461. https://doi.org/10.2337/dc06-0360CrossRefPubMed

15.

Choi, M. R. (2021). Inside the pathophysiological mechanisms of cardiometabolic diseases: The other pandemic to fight. European Journal of Physiology, 474, 1–4.CrossRefPubMed

16.

Cioffi, C. L., Dobri, N., Freeman, E. E., Conlon, M. P., Chen, P., Stafford, D. G., Schwarz, D. M., Golden, K. C., Zhu, L., Kitchen, D. B., Barnes, K. D., Racz, B., Qin, Q., Michelotti, E., Cywin, C. L., Martin, W. H., Pearson, P. G., Johnson, G., & Petrukhin, K. (2014). Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease. Journal of Medicinal Chemistry, 57, 7731–7757. https://doi.org/10.1021/jm5010013CrossRefPubMedPubMedCentral

17.

DeFronzo, R. A., & Ferrannini, E. (1991). Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14(3), 173–194.CrossRefPubMed

18.

Delucchi, F., Berni, R., Frati, C., Cavalli, S., Graiani, G., Sala, R., Chaponnier, C., Gabbiani, G., Calani, L., Rio, D. D., et al. (2012). Resveratrol treatment reduces cardiac progenitor cell dysfunction and preventsmorpho-functional ventricular remodeling in type-1 diabetic rats. PLoS ONE, 7, e39836.CrossRefPubMedPubMedCentral

19.

Dobri, N., Qin, Q., Kong, J., Yamamoto, K., Liu, Z., Moiseyev, G., Ma, J. X., Allikmets, R., Sparrow, J. R., & Petrukhin, K. (2013). A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Investigative Ophthalmology & Visual Science, 54, 85–95. https://doi.org/10.1167/iovs.12-10050CrossRef

20.

El-Sayed, M. M., Ghareeb, D. A., Talat, H. A., & Sarhan, E. M. (2013). High fat diet induced insulin resistance and elevated retinol binding protein 4 in female rats; treatment and protection with Berberis vulgaris extract and vitamin A. Pakistan Journal of Pharmaceutical Sciences, 26, 1189–1195.PubMed

21.

Graham, T. E., Yang, Q., Blüher, M., Hammarstedt, A., Ciaraldi, T. P., Henry, R. R., Wason, C. J., Oberbach, A., Jansson, P. A., Smith, U., & Kahn, B. B. (2006). Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New England Journal of Medicine, 354, 2552–2563. https://doi.org/10.1056/NEJMoa054862CrossRefPubMed

22.

Grant, S. J., Bin, Y. S., Kiat, H., & Chang, D. H. (2012). The use of complementary and alternative medicine by people with cardiovascular disease: A systematic review. BMC Public Health, 12, 299.CrossRefPubMedPubMedCentral

23.

Guilbault, C., De Sanctis, J. B., Wojewodka, G., Saeed, Z., Lachance, C., Skinner, T. A., Vilela, R. M., Kubow, S., Lands, L. C., Hajduch, M., Matouk, E., & Radzioch, D. (2008). Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. American Journal of Respiratory Cell and Molecular Biology, 38, 47–56. https://doi.org/10.1165/rcmb.2007-0036OCCrossRefPubMed

24.

Haider, D. G., Schindler, K., Mittermayer, F., Müller, M., Nowotny, P., Rieger, A., Luger, A., Ludvik, B., & Wolzt, M. (2007). Effect of rosiglitazone on visfatin and retinolbinding protein-4 plasma concentrations in HIV-positive patients. Clinical Pharmacology and Therapeutics, 81, 580–585. https://doi.org/10.1038/sj.clpt.6100047CrossRefPubMed

25.

Higgins, L. S., & Depaoli, A. M. (2010). Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. The American Journal of Clinical Nutrition, 91, 267S-272S. https://doi.org/10.3945/ajcn.2009.28449ECrossRefPubMed

26.

Hu, H., Xu, M., Qi, R., Wang, Y., Wang, C., Liu, J., Luo, L., Xia, L., & Fang, Z. (2015). Sitagliptin downregulates retinol-binding protein 4 and upregulates glucose transporter type 4 expression in a type 2 diabetes mellitus rat model. International Journal of Clinical and Experimental Medicine, 8, 17902–17911.PubMedPubMedCentral

27.

Kilicarslan, M., de Weijer, B. A., Simonyte, S. K., Aryal, P., Ter Horst, K. W., Cakir, H., Romijn, J. A., Ackermans, M. T., Janssen, I. M., & Berends., F.J., van de Laar A.W., Houdijk A.P., Kahn B.B., Serlie M.J. (2020). RBP4 increases lipolysis in human adipocytes and is associated with increased lipolysis and hepatic insulin resistance in obese women. The FASEB Journal, 34, 6099–6110. https://doi.org/10.1096/fj.201901979RRCrossRefPubMedPubMedCentral

28.

Kim, N., & Priefer, R. (2021). Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development. European Journal of Medicinal Chemistry, 226, 113856.CrossRefPubMed

29.

Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., et al. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2224–2260. https://doi.org/10.1016/S0140-6736(12)61766-8CrossRefPubMedPubMedCentral

30.

Lobb, A. (2009). Hepatoxicity associated with weight-loss supplements: A case for better post-marketing surveillance. World Journal of Gastroenterology., 15(14), 1786–1787.CrossRefPubMedPubMedCentral

31.

Mark, M., Ghyselinck, N. B., & Chambon, P. (2006). Function of retinoid nuclear receptors: Lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annual Review of Pharmacology and Toxicology, 46, 451–480. https://doi.org/10.1146/annurev.pharmtox.46.120604.141156CrossRefPubMed

32.

Mata, N. L., Lichter, J. B., Vogel, R., Han, Y., Bui, T. V., & Singerman, L. J. (2013). Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina, 33, 498–507. https://doi.org/10.1097/IAE.0b013e318265801dCrossRefPubMed

33.

Mercader, J., Palou, A., & Bonet, M. L. (2011). Resveratrol enhances fatty acid oxidation capacity and reduces resistin and Retinol-Binding Protein 4 expression in white adipocytes. Journal of Nutritional Biochemistry, 22, 828–834. https://doi.org/10.1016/j.jnutbio.2010.07.007CrossRefPubMed

34.

Moraes-Vieira, P. M., Yore, M. M., Dwyer, P. M., Syed, I., Aryal, P., & Kahn, B. B. (2014). RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metabolism, 19(3), 512–526.CrossRefPubMedPubMedCentral

35.

Motani, A., Wang, Z., Conn, M., Siegler, K., Zhang, Y., Liu, Q., Johnstone, S., Xu, H., Thibault, S., Wang, Y., Fan, P., Connors, R., Le, H., Xu, G., Walker, N., Shan, B., & Coward, P. (2009). Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. Journal of Biological Chemistry, 284, 7673–7680. https://doi.org/10.1074/jbc.M809654200CrossRefPubMedPubMedCentral

36.

Napoli, J. L. (1996). Biochemical pathways of retinoid transport, metabolism, and signal transduction. Clinical Immunology and Immunopathology, 80, S52–S62. https://doi.org/10.1006/clin.1996.0142CrossRefPubMed

37.

Pamela A.N, Nankam M.B. (2021). Retinol-binding protein 4 in obesity and metabolic dysfunctions. Molecular and Cellular Endocrinology.

38.

Pan, M. H., & WL Chang.WL, Lin- Shiau SY, Ho CT, Lin JK. (2001). Potential role of Garcinol as anti-cancer agent. Journal of Agriculture and Food Chemistry., 29(3), 1464–1474.CrossRef

39.

Pang, B., Zhao, L. H., Zhou, Q., Zhao, T. Y., Wang, H., Gu, C. J., et al. (2015). Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol, 2015, 12.CrossRef

40.

Perduca, M., Nicolis, S., Mannucci, B., Galliano, M., & Monaco, H. L. (2018). Human plasma retinol-binding protein (RBP4) is also a fatty acid-binding protein. Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids, 1863, 458–466. https://doi.org/10.1016/j.bbalip.2018.01.010CrossRefPubMed

41.

Pereira, A. S. P., Banegas-Luna, A. J., Peña-García, J., Pérez-Sánchez, H., & Apostolides, Z. (2019). Evaluation of the Anti-Diabetic Activity of Some Common Herbs and Spices: Providing New Insights with Inverse Virtual Screening. Molecules, 24, 4030–4071. https://doi.org/10.3390/molecules24224030CrossRefPubMedPubMedCentral

42.

Prabhakar, P. K., & Doble, M. (2008). A target based therapeutic approach towards diabetes mellitus using medicinal plants. Current Diabetes Review, 4, 291–308. https://doi.org/10.2174/157339908786241124CrossRef

43.

Prasetyastuti, S., Sadewa, A. H., & Mustofa,. (2016). Effect of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one (Swietenia macrophylla king seed) on retinol binding protein-4 and phosphoenolpyruvate carboxykinase gene expression in type 2 diabetic rats. Rom J Diabetes Nutr Metab Dis., 23(3), 255–265.

44.

Radu, R. A., Han, Y., Bui, T. V., Nusinowitz, S., Bok, D., Lichter, J., Widder, K., Travis, G. H., & Mata, N. L. (2005). Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: A potential therapy for treatment of lipofuscin-based retinal diseases. Investigative Ophthalmology & Visual Science, 46, 4393–4401. https://doi.org/10.1167/iovs.05-0820CrossRef

45.

Rauf, A., Imran, M., Suleria, H. A. R., Ahmad, B., Peters, D. G., & Mubarak, M. S. (2017). A comprehensive review of the health perspectives of resveratrol. Food & Function, 8, 4284–4305.CrossRef

46.

Rehman, M., Akhtar, N., & Mustafa, R. (2017). Antibacterial and antioxidant potential of stem bark extract of Bombax ceiba collected locally from South Punjab area of Pakistan. African Journal of Traditional, Complementary and Alternative Medicines, 14(2), 9–15.CrossRef

47.

Salehi, B., Mishra, A. P., Nigam, M., Sener, B., Kilic, M., Sharifi-Rad, M., Fokou, P. V. T., Martins, N., & Sharifi-Rad, J. (2018). Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines, 6, 91.CrossRefPubMedPubMedCentral

48.

Sarega, N., Imam, M. U., Esa, N. M., Zawawi, N., & Ismail, M. (2016). Effects of phenolic-rich extracts of Clinacanthus nutans on high fat and high cholesterol diet-induced insulin resistance. BMC Complementary and Alternative Medicine, 16, 88–98.CrossRefPubMedPubMedCentral

49.

Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 87, 4–14. https://doi.org/10.1016/j.diabres.2009.10.007CrossRefPubMed

50.

Stefan, N., Hennige, A. M., Staiger, H., Machann, J., Schick, F., Schleicher, E., Fritsche, A., & Haring, H. U. (2007). High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care, 30, 1173–1178. https://doi.org/10.2337/dc06-2342CrossRefPubMed

51.

Sun, Q., Kiernan, U. A., Shi, L., Phillips, D. A., Kahn, B. B., Hu, F. B., Manson, J. E., Albert, C. M., & Rexrode, K. M. (2013). Plasma retinol-binding protein 4 (RBP4) levels and risk of coronary heart disease: A prospective analysis among women in the nurses’ health study. Circulation, 127, 1938–1947. https://doi.org/10.1161/CIRCULATIONAHA.113.002073CrossRefPubMedPubMedCentral

52.

Sun, X., Zhang, Z., Ning, H., Sun, H., & Ji, X. (2017). Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: A randomized and double-blind trial. Metabolic Brain Disease, 32, 773–778. https://doi.org/10.1007/s11011-017-9958-7CrossRefPubMed

53.

Tabeshpour, J., Imenshahidi, M., & Hosseinzadeh, H. (2017). A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iranian Journal of Basic Medical Sciences, 20, 557–568. https://doi.org/10.22038/IJBMS.2017.8682CrossRefPubMedPubMedCentral

54.

Testa, R., Bonfigli, A., Genovese, S., De Nigris, V., & Ceriello, A. (2016). The possible role of flavonoids in the prevention of diabetic complications. Nutrients, 8, 310.CrossRefPubMedPubMedCentral

55.

The University of Edinburgh (2020). Cardiometabolic Diseases. https://www.ed.ac.uk/medicine-vet-medicine/our-research/research-themes/cardiometabolic-diseases

56.

Torabi, R., Ghourchian, H., Amanlou, M., & Pasalar, P. (2017). Aptamer-conjugated calcium phosphate nanoparticles for reducing diabetes risk via retinol binding protein 4 inhibition. Canadian Journal of Diabetes, 41, 305–311. https://doi.org/10.1016/j.jcjd.2016.11.001CrossRefPubMed

57.

Vasudeva, N., Yadav, N., & Sharma, S. K. (2012). Natural products: A safest approach for obesity. Chinese Journal of Integrative Medicine, 18, 473–480. https://doi.org/10.1007/s11655-012-1120-0CrossRefPubMed

58.

Vendrame, S., Zhao, A., Merrow, T., & Klimis-Zacas, D. (2014). The Effects of Wild Blueberry Consumption on Plasma Markers and Gene Expression Related to Glucose Metabolism in the Obese Zucker Rat. Journal of Medicinal Food, 00, 1–6.

59.

Veronesi, U., Mariani, L., Decensi, A., Formelli, F., Camerini, T., Miceli, R., Di Mauro, M. G., Costa, A., Marubini, E., Sporn, M. B., & De Palo, G. (2006). Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Annals of Oncology, 17, 1065–1071. https://doi.org/10.1093/annonc/mdl047CrossRefPubMed

60.

Vijayalakshmi, K., Nadhiya, K., Haripriya, D., & Ranjani, R. (2014). In silico Docking Analysis of Secondary Metabolites of Bauhinia variegata and Garcinia cambogia With Retinol Binding Protein4 as Target for Obesity. International Journal of Pharmacognosy and Phytochemical Research, 6(3), 636–642.

61.

Vinayagam, R., & Xu, B. (2015). Antidiabetic properties of dietary flavonoids: A cellular mechanism review. Nutri. Metab., 12, 60.CrossRef

62.

Wang, Y (2014).Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.Bioorg. Med. Chem. Lett, 24 (13) (2014), pp. 2885–2891

63.

Yan, F., Sun, X., & Xu, C. (2018). Protective effects of resveratrol improve cardiovascular function in rats with diabetes. Experimental and Therapeutic Medicine, 15, 1728–1734.PubMed

64.

Yang, Q., Graham, T. E., Mody, N., Preitner, F., Peroni, O. D., Zabolotny, J. M., Kotani, K., Quadro, L., & Kahn, B. B. (2005). Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 436, 356–362.CrossRefPubMed

65.

Yanovski, S. Z., & Yanovski, J. A. (2014). Long-term drug treatment for obesity: A systematic and clinical review. JAMA, 311, 74–86. https://doi.org/10.1001/jama.2013.281361CrossRefPubMedPubMedCentral

66.

Yao-Borengasser, A., Varma, V., Bodles, A. M., Rasouli, N., Phanavanh, B., Lee, M. J., Starks, T., Kern, L. M., Spencer, H. J., III., Rashidi, A. A., MacGehee, R. E., Jr., Fried, S. K., & Kern, P. A. (2007). Retinol binding protein 4 expression in humans: Relationship to insulin resistance, inflammation, and response to pioglitazone. Journal of Clinical Endocrinology and Metabolism, 92, 2590–2597. https://doi.org/10.1210/jc.2006-0816CrossRefPubMed

67.

Zabetian-Targhi, F., Mahmoudi, M. J., Rezaei, N., & Mahmoudi, M. (2015). Retinol binding protein 4 in relation to diet, inflammation, immunity, and cardiovascular diseases. Advances in Nutrition, 6, 748–762. https://doi.org/10.3945/an.115.008292CrossRefPubMedPubMedCentral

68.

Zakaria, Z., Othman, Z. A., Nna, V. U., & Mohamed, M. (2021). The promising roles of medicinal plants and bioactive compounds on hepatic lipid metabolism in the treatment of non-alcoholic fatty liver disease in animal models: Molecular targets. Archives of Physiology and Biochemistry. https://doi.org/10.1080/13813455.2021.1939387CrossRefPubMed

69.

Zanardi, S., Serrano, D., Argusti, A., Barile, M., Puntoni, M., & Decensi, A. (2006). Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Canc., 13, 51–68. https://doi.org/10.1677/erc.1.00938CrossRef

70.

Zanotti, G., Marcello, M., Malpeli, G., Folli, C., Sartori, G., & Berni, R. (1994). Crystallographic studies on complexes between retinoids and plasma retinol-binding protein. Biological Chemistry, 269, 29613–29620. https://doi.org/10.1016/S0021-9258(18)43925-7CrossRef

71.

Zhou, Z., Chen, H., Ju, H., & Sun, M. (2017). Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Lipids in Health and Disease, 16, 180. https://doi.org/10.1186/s12944-017-0566-7CrossRefPubMedPubMedCentral

72.

Zhu, C., Xiao, Y., Liu, X., Han, J., Zhang, J., Wei, L., & Jia, W. (2015). Pioglitazone lowers serum retinol binding protein 4 by suppressing its expression in adipose tissue of obese rats. Cellular Physiology and Biochemistry, 35, 778–788. https://doi.org/10.1159/000369737CrossRefPubMed

Title: Targeting Retinol-Binding Protein 4 (RBP4) in the Management of Cardiometabolic Diseases
Authors: Cecilia Oluwamodupe
Adesola Oluwaseun Adeleye
Publication date: 16-08-2023
Publisher: Springer US
Keywords: Insulins
Insulins
Obesity
Obesity
Published in: Cardiovascular Toxicology / Issue 9-10/2023
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-023-09803-8

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Targeting Retinol-Binding Protein 4 (RBP4) in the Management of Cardiometabolic Diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9-10/2023

Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways

COMP Improves Ang-II-Induced Atrial Fibrillation via TGF-β Signaling Pathway

Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer

Klotho/FGF23 Axis Regulates Cardiomyocyte Apoptosis and Cytokine Release through ERK/MAPK Pathway

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page